

5 Literaturverzeichnis

- Adachi W, Koike S, Nimura Y, Koide N, Iida F, Du XQ, Ping YM, He M, Chen LQ, Zhang MD, Zhang HL. Clinicopathologic characteristics and postoperative outcome in Japanese and Chinese patients with thoracic esophageal cancer. *World J Surg* 1996; 20:332-336.
- Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. *J Biol Chem* 2004; 279:1713-1719.
- Aihara T, Noguchi S, Miyoshi Y, Nakano H, Sasaki Y, Nakamura Y, Monden M, Imaoka S. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. *Hepatology* 1998; 28:86-89.
- Albanell J, Rojo F und Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. *Semin Oncol* 2001; 28: 56-66.
- Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? *Oncologist* 2002; 7 Suppl 4:31-39.
- Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. *Blood* 2004; 104:1816-1824.
- Bareiss D, Stabenow R, Müller R, Eisinger B, Stegmaier C, Däubler P, Zeitz M, Scherübl H. Current epidemiology of carcinoma of the esophagus and cardia in Germany. *Dtsch Med Wochenschr* 2002; 127:1367-1374.
- Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. *Eur J Cancer* 2001; 37:S16-S22.
- Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. *Oncologist* 2002; 7 Suppl 4:2-8.
- Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. *Int J Cancer* 2003; 107:873-877.
- Baserga R. The IGF-I receptor in cancer research. *Exp Cell Res* 1999; 253:1-6.
- Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. *Am J Physiol Endocrinol Metab* 2000; 278:967-976.
- Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. *Semin Oncol* 1999; 26:2-8.
- Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. *Oncogene* 2000; 19:2474-2488. *Br J Dermatol* 2001; 144:1169-1176.

- Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. *Oncogene* 2000; 19:2468-2473.
- Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. *Proc Natl Acad Sci* 1996; 93:7673-7678.
- Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, Schoenberg J, Greenberg R, Liff J, Schwartz A, Dosemeci M, Pottern L, Fraumeni JF. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. *Am J Epidemiol* 2001; 153:114-122.
- Burtress B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. *Expert Opin Biol Ther* 2005; 5:1085-1093.
- Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, KooH, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL. A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo. *Cancer Res* 2003; 63:8912-8921.
- Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D und Halpern AC. Cutaneous side-effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C225. *Br J Dermatol* 2001; 144:1169-1176.
- Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: From normal control of cellular events to tumorigenesis. *J Cell Physiol* 2003; 197:157-168.
- Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. *Br J Cancer* 2004; 5:221-230.
- Carter P. Improving the efficacy of antibody-based cancer therapies. *Nat Rev Cancer* 2001; 1:118-129.
- Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. *Cancer Res* 2002; 62:200-207.
- Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. *Br J Surg* 2001; 88:412-418.
- Chan-Hui PY, Weaver R. Human mitogen-activated protein kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades. *Biochem J* 1998; 336: 599-609.

- Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). *Proc Natl Acad Sci* 1998; 95:1091-1096.
- Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin Cancer Res* 2000; 6:2053-2063.
- Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. *Int J Cancer* 2002; 98:463-469.
- Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. *Clin Cancer Res* 2001; 7:2958-2970.
- Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. *Exp Cell Res* 2000; 256:34-41.
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; 351:337-345.
- Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. *Clin Cancer Res* 2002; 8:3438-3444.
- El Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. *Hepatology* 2001; 33:62-65.
- Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. *Mol Cell Biol* 1999; 19:5308-5315.
- Faiss S, Scherübl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. *Recent Results Cancer Res* 1996; 142:193-207.
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. *IARC Cancer Base No 5 Version 2 0 Lyon, France: IARC Press; 2004.*
- Funkunaga K, Kawano T. Akt is a molecular target for signal transduction therapy in brain ischemic insult. *J Pharmacol Sci* 2003; 92:317-327.
- Garber K. IGF-1: Old Growth Factor Shines as New Drug Target. *JNCI* 2005; 97:790-793.

- Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. *Oncogene* 2001; 20:2499-2513.
- García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Graus Porta D, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. *Cancer Cell* 2004; 5:231-239.
- ^aGiaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters G J, van der Vijgh WJ, Smith R, Averbuch S, Fandi A. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. *Ann Oncol* 2004; 15:831-838.
- ^bGiaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. *J Clin Oncol* 2004; 22:777-784.
- Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. *J Biol Chem* 2002; 277:27643-27650.
- Grimberg A, Cohen P. Role of Insulin-Like Growth Factors and Their Binding Proteins in Growth Control and Carcinogenesis. *J Cell Physiol* 2000; 183:1-9.
- Grimberg A. Mechanisms by which IGF-1 may promote cancer. *Cancer Biol Ther* 2003; 2:630-635.
- Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. *J Natl Cancer Inst* 2003; 95:851-867.
- Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier Joffe E, Kornblihggtt AR, et al. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. *Int J Cancer* 1996; 65:812-820.
- Hanski, C, Scherübl H, Mann B. Colorectal cancer: New aspects of molecular biology and immunology and their clinical applications. *Ann NY Acad Sci* 2000; 910:1-273.
- Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. *Endocr Relat Cancer* 2004; 11:689-708.

- Harper ME, Goddard L, Glynn-Jones E, Assender J, Dutkowski CM, Barrow D, Dewhurst OL, Wakelin AE, Nicholson RI. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. *Prostate* 2002; 52:59-68.
- Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. *J Clin Oncol* 2004; 22:785-794.
- Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005; 23:5892-5899.
- Hofmann F, García-Echeverría C. Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer. *Drug Discov Today* 2005; 10:1041-1047.
- Höpfner M, Sutter AP, Beck NI, Barthel B, Maaser K, Jockers-Scherübl MC, Zeitz M, Scherübl H. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. *Int J Cancer* 2002; 101:210-216.
- Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. *Cancer Res* 2004; 64:5355-5362.
- Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. *Cancer Res* 1999; 59:1935-1940.
- Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. *Invest New Drugs* 1999; 17:259-269.
- Hui AM, Makuuchi M, Li X. Cell cycle regulators and human hepatocarcinogenesis. *Hepato gastroenterology* 1998; 45:1635-1642.
- Jakobisiak M, Golab J. Potential antitumor effects of statins. *Int J Oncol* 2003; 23:1055-1069.
- Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. *Oncogene* 1999; 28:6071-6077.
- Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science* 2002; 298:1911-1912.

- Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. *Proc Natl Acad Sci* 1983; 5:1337-1341.
- Kellerer M, Lammers R, Haring HU. Insulin signal transduction: possible mechanisms for insulin resistance. *Exp Clin Endocrinol Diabetes* 1999; 107:97-106.
- Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). *Curr Opin Oncol* 2001; 13:506-513.
- Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. *Cancer Res* 1996; 56:3831-3836.
- Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996; 87:159-170.
- Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. *Int J Cancer* 2004; 108:464-472.
- Kultz D, Madhany S, Burg MB. Hyperosmolality causes growth arrest of murine kidney cells. Induction of GADD45 and GADD153 by osmosensing via stress-activated protein kinase 2. *J Biol Chem* 1998; 273:13645-13651.
- Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the P42/P44MAPK and negatively by the p38/HOGMAPK pathway. *J Biol Chem* 1996; 271:20608-20616.
- LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. *Ann Intern Med* 1999; 122:54-59.
- LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. *Cancer Lett* 2003; 195:127-137.
- Li H, Yao SC. Surgical treatment for carcinoma of the oesophagus in Chinese language publications. *Br J Surg* 1997; 84:855-857.
- Lu D, Zhang D, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced anti-tumor activity. *J Biol Chem* 2005; 280:19665-19672.

- Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. *Clin Cancer Res* 2004; 10:6487-6501.
- McMillan L, Butcher SK, Pongracz J, Lord JM. Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: Differential activation of PKC and MAP kinases. *Br J Cancer* 2003; 88:748-753.
- Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. *Endocr Relat Cancer* 2001; 8:3-9.
- Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. *J Cell Biochem* 1988; 38:87-97.
- Mita A, Farouzes B, Hidalgo M. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (HER1/EGFR-TK) inhibitor erlotinib (OSI-774; Tarceva) in combination with docetaxel. *Eur J Cancer* 2002; 38:53-59.
- Mitsiades CS, Mitsiades NS, McCullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC, Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and other solid tumors. *Cancer Cell* 2004; 5:221-230.
- Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. *J Endocrinol* 2002; 175:19-31.
- Moore MJ, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Parulekar W. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada clinical trials group (NCIC-CTG). *Gastrointestinal Cancers Symposium* 2005.
- Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. *Cancer Res* 1997; 57:4838-4848.
- Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. *Endocrinology* 1995; 136:4298-4303.
- Neuhaus H. Vorsorge zur Prävention und Früherkennung des kolorektalen Karzinoms. *Deutsches Ärzteblatt* 1998; 95: B442-B449.

- Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. *Ann Oncol* 2001; 12 Suppl 2:S111-S114.
- Öberg K. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. *Ann N Y Acad Sci* 1994; 733:46-55.
- O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst* 2004; 96:1420-1425.
- O'Connor R. Regulation of IGF-I receptor signaling in tumor cells. *Horm Metab Res* 2003; 35:771-777.
- Oliviera S, van Bergen En Henegouwen PM, Storm G, Schifflers RM. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. *Expert Opin Biol Ther* 2006; 6:605-617.
- Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. *Cancer* 2000; 89:74-82.
- Parizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. *Endocrinology* 1997; 138:1427-1433.
- Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncol* 2001; 2:533-543.
- Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. *Clin Cancer Res* 2002; 8:2273-2285.
- Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. *Cancer Res* 1993; 53:1102-1106.
- Piret JP, Arnould T, Fuks B, Chatelain P, Remacle J, Michiels C. Mitochondria permeability transition-dependent tert-butyl hydroperoxide-induced apoptosis in hepatoma HepG2 cells. *Biochem Pharmacol* 2004; 67:611-620.
- Pollak, M.N. Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. *Nat Rev Cancer* 2004; 4:505-518.
- Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. *Proc Natl Acad Sci* 1994; 91:2181-2185.
- Pratesi G, Perego P, Zunino F. Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. *Biochem Pharmacol* 2001; 61:381-386.

- Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. *Journal of Immunotherapy* 1996; 19:419-427.
- Ratjan MJ, George CM, Janisch L, Kindler HL, Ryan C, Wood DL, Nadler PI, Vokes EE. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. *Proc Am Soc Clin Oncol* 2002; 21:76.
- Rauci A, Laplantine E, Mansukhani A, Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. *J Biol Chem* 2004; 279:1747-1756.
- Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. *Cancer Res* 1995; 55:3739-3741.
- Rieder CL, Khodjakov A. Mitosis and checkpoints that control progression through mitosis in vertebrate somatic cells. *Prog Cell Cycle Res* 1997; 3:301-312.
- Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. *Lab Invest* 1995; 73:311-331.
- Rubinfeld H, Seger R. The ERK cascade: A prototype of MAPK signaling. *Mol Biotechnol* 2005; 31:151-174.
- Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 1995; 19:183-232.
- Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. *Horm Metab Res* 2003; 35:685-693.
- Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). *Carcinogenesis* 1998; 19:2121-2128.
- Schernhammer ES, Tranah GJ, Giovannucci E, Chan AT, Ma J, Colditz DA, Hunter DJ, Willet WC, Fuchs CS. Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. *Br J Cancer* 2006; 94:928-934.
- Schmoll HJ. Kolorektales Karzinom, in: *Kompendium Internistische Onkologie*. Springer Verlag Berlin 1997; 2:694-759.
- Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. *Cancer Res* 2005; 65:3868-3876.

- Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). *Br J Cancer* 2002; 86:456-462.
- Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. *JAMA* 2002; 287:1982-1986.
- Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening. *Semin Liver Dis* 2005; 25:143-154.
- Singh R, Pervin S, Chaudhuri G. Caspase-8-mediated BID cleavage and release of mitochondrial cytochrome c during nomega-hydroxy-L-arginine-induced apoptosis in MDA-MB-468 cells. antagonistic effects of L-ornithine. *J Biol Chem* 2002; 277:37630-37636.
- Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. *Clin Cancer Res* 2000; 6:4885-4892.
- Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. *Physiol Rev* 1996; 76:1005-1026.
- Sun L, Gong R, Wan B, Huang X, Wu C, Zhang X, Zhao S, Yu L. GADD45gamma, down-regulated in 65% hepatocellular carcinoma (HCC) from 23 chinese patients, inhibits cell growth and induces cell cycle G2/M arrest for hepatoma Hep-G2 cell lines. *Mol Biol Rep* 2003; 30:249-253.
- Sutter AP, Maaser K, Barthel B, Scherübl H. Ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in oesophageal cancer cells: Involvement of the p38MAPK signalling pathway. *Br J Cancer* 2003; 89:564-572.
- Sutter AP, Maaser K, Höpfner M, Huether A, Schuppan D, Scherübl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. *J Hepatol* 2004; 43:808-816.
- Takahashi M, Saito H, Okuyama T, Miyashita T, Kosuga M, Sumisa F, Yamada M, Ebinuma H, Ishii H. Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody-mediated apoptosis. *J Hepatol* 1999; 31:315-322.
- Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: Deregulation in cell cycling and apoptosis. *Virchows Arch* 2002; 440:345-352.
- Toyoda H, Komurasaki T, Uchida D, Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. *Biochem J* 1997; 326:69-75.

- Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. *Proc Natl Acad Sci* 1992; 89:4874-4878.
- Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski M, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. *Science* 1993; 259:94-97.
- Vairapandi M, Balliet AG, Fornace AJ, Hoffman B, Liebermann DA. The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21WAF1/CIP1. *Oncogene* 1996; 12:2579-2594.
- Vander Heiden MG, Chandel NS, Schumacker PT und Thompson CB. Bcl-XL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. *Mol Cell* 1999; 3:159-167.
- von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. *Cancer Res* 2000; 60:4573-4581.
- Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. *Histol Histopathol* 1998; 13:521-530.
- Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. *Clin Cancer Res* 2005; 11:1563-1571.
- Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N. Prognostic significance of Bcl-XL in human hepatocellular carcinoma. *Surgery* 2004; 135:604-612.
- Watanabe T, Shintani A, Nakata M, Shing Y, Folkman J, Igarashi K, Sasada R. Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. *J Biol Chem* 1994; 269:9966-9973.
- Wells A. EGF receptor. *Int J Biochem Cell Biol* 1999; 31:637-643.
- Wilkinson MG, Millar JB. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. *FASEB J* 2000; 14:2147-2157.
- Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol Ther* 1999; 82:241-250.
- Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE. Altered gene expression in drug-resistant human breast cancer cells. *Clin Cancer Res* 1997; 3:2405-2414.

- Xu JM, Azzariti A, Colucci G, Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. *Cancer Chemother Pharmacol* 2003; 52:442-448.
- Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, Zhou X, Zeng Z, Li T, Yang Y, Hoffman AR. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. *Clin Cancer Res* 2003; 9:2719-2726.
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001; 2:127-137.
- Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. *J Natl Cancer Inst* 2000; 92:1472-1489.
- Zahradka P, Werner J, Yau L. Expression and regulation of the insulinlike growth factor-1 receptor by growing and quiescent H4IIE hepatoma. *Biochim Biophys Acta* 1998; 1375:131-139.
- Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G. Mitochondrial control of nuclear apoptosis. *J Exp Med* 1998; 183:1533-1544.
- Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. *Breast Cancer Res* 2000; 2:170-175.
- Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, Fang B. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. *Oncogene* 2004; 23:4984-4992.
- Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. *J Biol Chem* 2000; 275:15099-15105.